Clinical Characteristics of Cerebral Venous Sinus Thrombosis in Patients with Systemic Lupus Erythematosus: A Single-Centre Experience in China

Table 3

Clinical comparison of SLE patients with CVST and without CVST.

Characteristics	SLE with CVST ( = 17)	SLE without CVST ( = 51)	value
Age (years, mean ± SD)	28.4 ± 11.3	32.7 ± 11.1	0.168
Gender (F/M)	12/5	43/8	0.620
Disease duration (months, mean ± SD)	30.0 ± 39.6	38.2 ± 33.0	0.400
Fever	6/17 (35.3%)	24/51 (47.1%)	0.398
Rash	5/17 (41.2%)	21/51 (41.2%)	0.300
Musculoskeletal involvement	6/17 (35.3%)	27/51 (52.9%)	0.207
Hemocytopenia	10/17 (58.8%)	33/51 (64.7%)	0.516
Lymphopenia	4/17 (23.5%)	18/51 (35.2%)	0.320
Anemia	9/17 (52.9%)	19/51 (37.3%)	0.255
Thrombocytopenia	10/17 (58.8%)	12/51 (23.5%)
Serositis	5/17 (29.4%)	11/51 (21.6%)	0.523
Kidney involvement	12/17 (70.6%)	30/51 (58.8%)	0.387
Gastrointestinal involvement	1/17 (5.9%)	7/51 (13.7%)	0.669
Other neurological manifestations	6/17 (35.3%)	11/51 (21.6%)	0.334
Cardiovascular involvement	2/17 (11.8%)	7/51 (13.7%)	1.000
Serum albumin (g/L, mean ± SD)	29.8 ± 6.9	30.7 ± 8.6	0.715
ESR (mm/1 h, mean ± SD)	42.2 ± 24.6	38.0 ± 24.5	0.537
Hypocomplementemia	12/17 (70.6%)	37/51 (72.5%)	1.000
Anti-dsDNA	8/17 (47.1%)	35/51 (68.6%)	0.110
Anti-Sm	6/17 (35.3%)	19/51 (37.3%)	0.885
Anti-RNP	5/17 (29.4%)	24/51 (47.1%)	0.203
Anti-SSA	12/17 (70.6%)	28/51 (54.9%)	0.198
Anti-SSB	1/17 (5.9%)	6/51 (11.8%)	0.670
Anti-rRNP	3/17 (17.6%)	12/51 (23.5%)	0.745
APL	7/17 (41.2%)	8/51 (15.7%)
SLEDAI (CVST included, mean ± SD)	20.1 ± 3.7	12.8 ± 5.3

< 0.05.
Anti-dsDNA: antidouble stranded DNA antibody, Anti-Sm: anti-Smith antibody, Anti-SSA: anti-SSA antibody, Anti-SSB: anti-SSB antibody, Anti-RNP: anti-u1 small-nuclear RNA-protein antibody, Anti-rRNP: antiribosomal RNA-protein antibody, APL: antiphospholipid antibody, and SLEDAI: SLE disease activity index.